<DOC>
	<DOCNO>NCT02173691</DOCNO>
	<brief_summary>The objective study compare long-term ( six month ) bronchodilator efficacy safety tiotropium inhalation capsule , salmeterol inhalation aerosol placebo inpatient COPD .</brief_summary>
	<brief_title>Efficacy Safety Tiotropium Compared Salmeterol Placebo Patients With Chronic Obstructive Bronchitis ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Age ≥ 40 year . A diagnosis relatively stable , moderate severe COPD : Screening FEV1 ≤ 60 % predict normal value ( calculate accord European Community Coal Steel ( ECCS ) criteria screen FEV1/FVC ≤ 70 % Smoking history ≥ 10 packyears ( packyear 20 cigarette per day one year equivalent ) Ability train proper use HandiHaler® device Metered Dose Inhaler ( MDI ) . Ability perform study related test include Shuttle Walking Test , acceptable pulmonary function test , include Peak expiratory flow rate ( PEFR ) measurement , maintenance diary card record . Ability give write informed consent accordance Good Clinical Practice local regulation . Clinically significant disease COPD . Patients clinically relevant abnormal baseline haematology , blood chemistry urinalysis , abnormality defines disease list exclusion criterion , exclude . All patient serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 80 IU/L , serum glutamic pyruvic transaminase ( SGPT ) &gt; 80 IU/L , bilirubin &gt; 2.0 mg/dL creatinine &gt; 2.0 mg/dL exclude regardless clinical condition . A recent history ( i.e. , one year less ) myocardial infarction . Any cardiac arrhythmia require drug therapy hospitalisation heart failure within past three year . Inability abstain regular daytime use oxygen therapy 1 hour per day . Known active tuberculosis . History cancer within last five year ( exclude basal cell carcinoma ) History lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis . Patients undergone thoracotomy pulmonary resection . Any upper respiratory infection past six week prior screen visit runin period . Current participation pulmonary rehabilitation programme completion pulmonary rehabilitation programme six week prior screen visit . Known hypersensitivity anticholinergic drug , salmeterol , component lactose powder capsule MDI delivery system . Known symptomatic prostatic hypertrophy bladder neck obstruction . Patients know narrowangle glaucoma . Current treatment cromolyn sodium nedocromil sodium . Current treatment antihistamine ( H1 receptor antagonist ) . Oral corticosteroid medication unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisolone per day 20 mg every day . Current use βblocker medication . Current treatment monoamine oxidase inhibitor tricyclic antidepressant . Pregnant nursing woman woman childbearing potential use medically approve mean contraception . Patients history asthma , allergic rhinitis atopy total blood eosinophil count &gt; 600mm3 . History and/or active significant alcohol drug abuse . Concomitant recent use investigational drug within one month six half life ( whichever great ) prior screen visit . Changes pulmonary therapeutic plan within six week prior screen visit . Inability comply medication restriction specify Section 4.2 trial protocol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>